Bioscience

ImmuneRegen BioSciences initiates strategic collaboration with MPI Research

April 21, 2010

By Flinn Foundation

[Source: Sys-Con] – ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), entered into a strategic collaboration with MPI Research today. Under the agreement, MPI Research will develop and perform preclinical, FDA-required safety studies and analytical research services in support of ImmuneRegen’s lead drug candidate, Homspera®, which are expected to enable Phase 1 human clinical studies. Mutually agreeable financial incentives have been incorporated into the terms of this agreement.

For more information: ImmuneRegen BioSciences(R) Initiates Strategic Collaboration With MPI Research to Accelerate Clinical Development of Lead Indications